RT-112 was established from the transitional cell carcinoma (histological grade G2) excised from a woman (age unknown) with untreated primary urinary bladder carcinoma in 1973.
This cell line became resistant by suczessively increasing the dose of Adriamycin implemented into the cell culture medium, with regard to a control concentration of Adriamycin of 0.1 µg/ml.